SCHEMBL698959

SCHEMBL698959

O=C(O)Cn1cc(CCNS(=O)(=O)c2ccc(Cl)cc2)c2ccccc21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 5/20 0.71
KCNH2 Q12809 2/20 0.68
HDAC1 Q13547 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
TBXA2R P21731 2/20 0.50
PTGDR2 Q9Y5Y4 1/20 0.49
KMT2A Q03164 1/20 0.48
MCL1 Q07820 1/20 0.48
HTR6 P50406 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698228 0.94 KCNA5 (0.64) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL10494268 0.90 KCNA5 (0.65) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL13021000 0.89 KCNA5 (0.71) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL10375360 0.85 KCNA5 (0.58) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL9814888 0.82 KCNA5 (0.56) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL9362957 0.80 KCNA5 (0.54) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL9363306 0.80 KCNA5 (0.65) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL13677405 0.78 KCNA5 (0.65) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL10367735 0.78 KCNA5 (0.59) KCNA5KCNH2HDAC1HDAC6HDAC3
SCHEMBL17943807 0.78 KCNA5 (0.55) KCNA5KCNH2HDAC1HDAC6HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST SHIONOGI & CO., LTD. 2009-10-15 US claimed
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2005-08-04 US claimed
WO-2021066136-A1 THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY 国立大学法人東京大学 2021-04-08 WO disclosed
EP-2423190-A1 Compounds Exhibiting PGD 2 Receptor Antagonism Shionogi&Co., Ltd. (JP) 2012-02-29 EP disclosed
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST SHIONOGI & CO., LTD. 2009-10-15 US disclosed
US-7534897-B2 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2009-05-19 US disclosed
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2005-08-04 US disclosed
EP-1505061-A1 COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM SHIONOGI & CO., LTD. (JP) 2005-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258922-A1 COMPOUND EXHIBITING PGD2 RECEPTOR ANTAGONIST CYSLTR2, CYSLTR1, HRH2 KCNA5 2720/4885KCNH2 2050/4885HDAC1 2165/4885
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism CYSLTR2, CYSLTR1, HRH2 KCNA5 2974/4885KCNH2 2475/4885HDAC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.